MedTrace Logo

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction

NCT01172756 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2014-11-04

No results posted yet for this study

Summary

The aim of this study is to assess whether single oral doses of Riociguat safely improve the cardiovascular function in patients with pulmonary hypertension associated with left ventricular diastolic dysfunction

Conditions

  • Hypertension, Pulmonary
  • Ventricular Dysfunction, Left

Interventions

DRUG

Riociguat (BAY63-2521)

0.5 mg single oral dose

DRUG

Riociguat (BAY63-2521)

1 mg single oral dose

DRUG

Riociguat (BAY63-2521)

2 mg single oral dose

DRUG

Placebo

single oral dose

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • Austria
  • Czechia
  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01172756 on ClinicalTrials.gov